Q2 Earnings Round-Up Part 2: Launches, Growth Still Face Challenges
Executive Summary
The pandemic created a tough environment for sales of both newly launched products and growing products, especially for small-to-medium enterprises. Scrip reviewed the second quarter earnings calls for several SMEs: some are continuing to feel pressure, and some are starting to recover. [See Part 1 for companies reporting a turnaround.]
You may also be interested in...
Finance Watch: Four New IPOs Hold Steady In First Days Of Trading
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline
Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.